• 1
    Neuberger J, Adams DH. What is the significance of acute liver allograft rejection. J Hepatol 1998; 29: 143150.
  • 2
    Calne RY. An opportunity in organ transplantation. Nat Med 1995; 1: 2022.
  • 3
    Ojo AO, Meier-Kriesche H-U, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 24052409.
  • 4
    Ramos HC, Reyes J, Abuelmagd K et al. Weaning of immunosuppression in long-term liver-transplant recipients. Transplantation 1995; 59: 212217.
  • 5
    Dousset B, Hubscher SG, Padbury RT et al. Acute liver allograft rejection is treatment always necessary? Transplantation 1993; 55: 529534.
  • 6
    Padbury RT, Gunson BK, Dousset B et al. Steroid withdrawal from long-term immunosuppression in liver allograft recipients. Transplantation 1993; 55: 789794.
  • 7
    Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5: 12981302,.
  • 8
    Lan F, Hayamizu K, Strober S. Cyclosporine facilitates chimeric and inhibits nonchimeric tolerance after posttransplant total lymphoid irradiation. Transplantation 2000; 69: 649655.
  • 9
    Wekerle T, Kurtz J, Bigenzahn S, Takeuchi Y, Sykes M. Mechanisms of transplant tolerance induction using costimulatory blockade. Curr Opin Immunol 2002; 14: 592.
  • 10
    Cosimi A. Calcineurin inhibitors are not antagonistic to tolerance induction. Transplant Proc 2002; 34: 13761377.
  • 11
    Millan MT, Shizuru JA, Hoffmann P et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 2002; 73: 13861391.
  • 12
    Millan MT, Shizuru JA, Hoffmann P et al. Mixed chimerism and donor-specific unresponsiveness without graft-versus-host disease after MHC-mismatched hematopoietic stem cell infusion and kidney transplantation [abstract 59]. Transplantation 2002; 74: 37.
  • 13
    Ferreira JV, Froud T, Caulfield A et al. Can enriched bone marrow infusion induce donor tolerance in solitary islet cell transplantation? [abstract 290] Transplantation 2002, 74.
  • 14
    Jordan MS, Riley MP, Von Boehmer H, Caton AJ. Anergy and suppression regulate CD4 (+) T cell responses to a self peptide. Eur J Immunol 2000; 30: 136144.
  • 15
    Wekerle T, Sayegh MH, Chandraker A, Swenson KG, Zhao Y, Sykes M. Role of peripheral clonal deletion in tolerance induction with bone marrow transplantation and costimulatory blockade. Transplant Proc 1999; 31: 680.
  • 16
    Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 System of T cell costimulation. Ann Rev Immunol 1996; 14: 233258.
  • 17
    Moreland LW, Alten R, Van den Bosch F et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002; 46: 14701479.
  • 18
    Adams AB, Shirasugi N, Durham MM et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 2002; 51: 265270.
  • 19
    Kirk AD, Tadaki DK, Celniker A et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 2001; 72: 377384.
  • 20
    Hausen B, Klupp J, Christians U et al. Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys. Transplantation 2001; 72: 11281137.
  • 21
    Vincenti F. What's in the pipeline: new immunosuppressive drugs in transplantation. Am J Transplant 2002; 2: 898903.
  • 22
    Schopf RE. IDEC-114 (IDEC). Curr Opin Invest Drugs 2001; 2: 635638.
  • 23
    Diabetogen press release, March 26, 2001.
  • 24
    Özkaynak E, Gao W, Shemmeri N et al. Importance of ICOS–B7RP:-1 costimulation in acute and chronic allograft rejection. Nat Immunol 2001; 2: 591596.
  • 25
    Guo L, Li XK, Funeshima N et al. Prolonged survival in rat liver transplantation with mouse monoclonal antibody against an inducible costimulator (ICOS). Transplantation 2002; 73: 10271032.
  • 26
    Nakamura Y, Yasunami Y, Hirakawa E et al. Acceptance of islet allografts in the liver of mice by blockade of an inducible costimulatory [abstract 462]. Transplantation 2002; 74: 160.
  • 27
    Kirk AD, Burkly LC, Batty DS et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686693.
  • 28
    IDEC press release, June 10, 2002.
  • 29
    Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98: 10471054.
  • 30
    Boon L, Laman JD, Ortiz-Buijsse A et al. Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys. Toxicology 2002; 174: 5365.
  • 31
    Isobe M, Yagita H, Okumura K, Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 1992; 255: 11251127.
  • 32
    Isobe M, Suzuki J, Yamazaki S et al. Regulation by differential development of Thl and Th2 cells in peripheral tolerance to cardiac allograft induced by blocking ICAM-1/LFA-1 adhesion. Circulation 1997; 96: 22472253.
  • 33
    Corbascio M, Ekstrand H, Osterholm C et al. CTLA4Ig combined with anti-LFA-1 prolongs cardiac allograft survival indefinitely. Transpl Immunol 2002; 10: 5561.
  • 34
    Papp K, Bissonnette R, Krueger JG et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001; 45: 665674.
  • 35
    Dedrick RL, Walicke P, Garovoy M. Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody. Transpl Immunol 2002; 9: 181186.
  • 36
    Vincenti F, Mendez R, Rajagopalan PR et al. A phase I/II trial of anti-CD11a monoclonal antibody in renal transplantation [abstract #562]. Am J Transplant 2001; 1 (Suppl. 1): 276.
  • 37
    Seville F, Vanhove B, Soullilou J-P. Mechanisms of tolerance induction: blockade of costimulation. Phil Trans R Soc London B 2001; 356: 649657.
  • 38
    Antilfa Study Group. Prospective study of anti-cd11a antibody in prevention of delayed graft function (dgf) in recipients of high-risk renal cadaver grafts [abstract 471]. Am J Transplant 2001; 1 (Suppl. 1): 253.
  • 39
    Suzuki J, Isobe M, Izawa A et al. Differential Th1 and Th2 cell regulation of murine cardiac allograft acceptance by blocking cell adhesion of ICAM-1/LFA-1 and VCAM-1/VLA-4. Transpl Immunol 1999; 7: 6572.
  • 40
    Hori J, Isobe M, Yamagami S, Tsuru T. Acceptance of second corneal allograft by combination of anti-VLA-4 and anti-LFA-1 monoclonal antibodies in mice. Transplant Proc 1998; 30: 200201.
  • 41
    Yang H, Issekutz TB, Wright JR Jr. Prolongation of rat islet allograft survival by treatment with monoclonal antibodies against VLA-4 and LFA-1. Transplantation 1995; 60: 7176.
  • 42
    Tubridy N, Behan PO, Capildeo R et al. The effect of anti-VLA4 integrin antibody on brain lesions activity in MS. The UK Antegren Study Group. Neurology 1999; 53: 466472.
  • 43
    Gordon FH, Hamilton MI, Donoghue S et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002; 16: 699705.
  • 44
    Ghosh S, Goldin E, Gordon FH et al. Natalizumab for Active Crohn's Disease. N Engl J Med 2003; 348: 2432.
  • 45
    Wekerle T, Blaha P, Langer F, Schmid M, Muehlbacher F. Tolerance through bone marrow transplantation with costimulation blockade. Transpl Immunol 2002; 9: 125133.
  • 46
    Wekerle T, Kurtz J, Ito H et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000; 6: 464469.
  • 47
    Durham MM, Bingaman AW, Adams AB et al. Administration of anti-CD40 ligand and donor bone marrow leads to hematopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000; 165: 14.
  • 48
    Chavin KD, Qin L, Lin J, Yagita H, Bromberg JS. Combined anti-CD2 and anti-CD3 receptor monoclonal antibodies induce donor-specific tolerance in a cardiac transplant model. J Immunol 1993; 151: 72497259.
  • 49
    Woodward JE, Qin L, Chavin KD et al. Blockade of multiple costimulatory receptors induces hyporesponsiveness: inhibition of CD2 plus CD28 pathways. Transplantation 1996; 62: 10111018.
  • 50
    Besse T, Malaise J, Mourad M et al. Prevention of rejection with BTI-322 after renal transplantation (results at 9 months). Transplant Proc 1997; 29: 24252426.
  • 51
    Przepiorka D, Phillips GL, Ratanatharathorn V et al. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood 1998; 92: 40664071.
  • 52
    Dehoux JP, Talpe S, Dewolf N et al. Effects on human and nonhuman primate immune response of a new rat anti-CD2 monoclonal antibody. Transplantation 2000; 69: 26222633.
  • 53
    Ellis N, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248255.
  • 54
    Sultan P, Schechner JS, McNiff JM et al. Blockade of CD2–LFA−3 interactions protects human skin allografts in immunodeficient mouse/human chimeras. Nat Biotechnol 1998; 15: 759762.
  • 55
    Kaplon RJ, Hochman PS, Michler RE et al. Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival. Transplantation 1996; 61: 356363.
  • 56
    Waldman H, Cobbold S. How do monoclonal antibodies induce tolerance? A role for infectious tolerance? A Review. Immunol 1998; 16: 619644.
  • 57
    Van der Lubbe PA, Reiter C, Breedveld FC et al. Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheumatism 1993; 36: 1375.
  • 58
    Honey K, Cobbold SP, Waldmann H. Dominant tolerance and linked suppression induced by therapeutic antibodies do not depend on Fas–FasL interactions. Transplantation 2001; 69: 16831689.
  • 59
    Kohlhaw K, Sack U, Lehmann I et al. The monoclonal anti-CD4 antibody RIB5/2 induces donor-specific tolerance in the high-responder liver transplant model in the rat. Transplant Proc 2001; 33: 23712373.
  • 60
    Guo Z, Wu T, Kirchhof N et al. Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection. Transplantation 2001; 71: 16561665.
  • 61
    Thiel MA, Takano T, Hawksworth N, Coster DJ, Williams KA. Low-dose, short-term treatment with anti-CD4 monoclonal antibody prolongs corneal allograft survival. Transplant Proc 2001; 33: 635636.
  • 62
    Newman R, Hariharan K, Reff M et al. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4 (+) T cells in chimpanzees. Clin Immunol 2001; 98: 164174.
  • 63
    Genmab press release, September 24, 2002.
  • 64
    Genmab press release, September 19, 2002.
  • 65
    Winsor-Hines D, Cobbold SP, Merrill CJ et al. Induction of durable, antigen specific tolerance in primates with a short therapeutic course of non-depleting anti-cd4 antibody [abstract 254]. 2nd Annual Meeting of the Federation of Clinical Immunology Societies, San Francisco, CA.
  • 66
    Woodle ES, Xu D, Zivin RA et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1 (Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999; 68: 608616.
  • 67
    Hering BJ, Kandaswamy R, Harmon JV et al. Insulin independence after single-donor islet transplantation in type 1 diabetes with hOKT3gamma1 (Ala-Ala), sirolimus, and tacrolimus therapy. Am J Transplant 2001; 1 (Suppl. 1): 180A.
  • 68
    Norman DJ, Vincenti F, De Mattos AM et al. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation 2000; 70: 17071712.
  • 69
    Trajkovic V. Nuvion protein design laboratories. Curr Opin Invest Drugs 2002; 3: 411414.
  • 70
    Friend PJ, Hale G, Chatenoud L et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 1999; 68: 16321637.
  • 71
    Thomas JM, Eckhoff DE, Contreras JL et al. Durable donor-specific T and B cell tolerance in rhesus macaques induced with peritransplantation anti-CD3 immunotoxin and deoxyspergualin: absence of chronic allograft nephropathy. Transplantation 2000; 69: 24972503.
  • 72
    Thompson J, Stavrou S, Weetall M et al. Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion. Protein Eng 2001; 14: 10351041.
  • 73
    Calne R, Friend P, Moffatt S et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 17011702.
  • 74
    Knechtle SJ, Pirsch JD, Becker BN et al. A pilot study of Campath-1H induction plus rapamycin monotherapy in renal transplantation [abstract 45]. Transplantation 2002; 74: 32.
  • 75
    Kirk AD, Hale DA, Hoffmann SC et al. Results from a human tolerance trial using campath-1h with and without infliximab [abstract 47]. Transplantation 2002; 74: 33.
  • 76
    Daller A, Woodside KJ, Meng T, Hu M, Gugliuzza KK, Hunter GC. Altered lymphocyte expression of fas and bcl-2 in renal transplant patients receiving induction therapy [abstract 3010]. Transplantation 2002; 74: 594.
  • 77
    Swanson SJ, Hale DA, Mannon RB, Harlan DM, Kleiner DE, Kirk AD. Sirolimus monotherapy in kidney transplantation following high dose thymoglobulin induction [abstract 13]. Transplantation 2002; 74: 22.
  • 78
    Corry R, Potdar S, Shapiro R et al. Pancreas and kidney-pancreas transplantation under a tolerogenic regimen of preconditioning with thymoglobulin and post-transplant tacrolimus [abstract 85]. Transplantation 2002; 74: 46.
  • 79
    Harris C, Bond G, Janson D et al. Thymoglobulin (rATG) single high dose pretreatment for human intestinal transplantation: lymphocyte depletion, drug levels and immune reconstitution [abstract 590]. Transplantation 2002; 74: 199.
  • 80
    Shapiro R, Scantlebury VP, Jordan ML et al. Kidney transplantation under a tolerogenic regimen of thymoglobulin preconditioning and post-transplant tacrolimus monotherapy [abstract 3343]. Transplantation 2002; 74: 673.
  • 81
    Abu-Elmagd KM, Bond GJ, Murase N et al. Tolerance for human intestinal transplantation [abstract 61]. Transplantation 2002; 74: 38.
  • 82
    Abu-Elmagd M, Bond G, Murase N et al. Graft immunomodulation and tolerance enhancing strategy for intestinal transplantation [abstract 640]. Transplantation 2002; 74: 218.
  • 83
    Fabre JW, Williams AF. Quantitative serological analysis of a rabbit anti-rat lymphocyte serum and preliminary biochemical characterisation of the major antigen recognised. Transplantation 1977; 23: 349359.
  • 84
    Warr GW, Marchalonis JJ. Glycoproteins of murine thymocyte and splenocyte surface membranes; binding to concanavalin A and recognition by heterologous antilymphocyte serum. Immunochemistry 1976; 13: 753758.
  • 85
    Bonnefoy-Berard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991; 51: 669673.
  • 86
    Luke PPW, O'Brien CA, Jevnikar AM, Zhong R. Anti-CD45RB: Monoclonal antibody-mediated transplantation tolerance. Curr Mol Med 2001; 1: 533543.
  • 87
    Rothstein DM, Livak MF, Kishimoto K et al. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J Immunol 2001; 166: 322329.